Biotech entity

American Vanguard

Company AVD

Every one of those 1 sits in a single category, pharma. American Vanguard is most often covered alongside Eric Wintemute, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.

Last mentioned: Mar 17, 2026

Entity pulse

Recent coverage · American Vanguard

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about American Vanguard

Every one of those 1 sits in a single category, pharma. American Vanguard is most often covered alongside Eric Wintemute, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. They are less corroborated than the beat average, carrying 3 original sources each against 3.3 for the same window. We currently track 1 Biotech story that mention American Vanguard, all published on March 17, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering American Vanguard. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Call

    Official earnings release and investor conference call held.

  2. SEC Filing

    Company files FY 2025 results with the SEC.

  3. SIMPAS Expansion

    Record adoption of SIMPAS technology during the peak U.S. growing season.

  4. Q1 Stabilization

    North American inventory levels stabilize following the 2024 destocking cycle.

  5. Transformation Launch

    AVD initiates a business transformation program to save $15M annually.

Stories mentioning American Vanguard 1

Pharma Neutral

American Vanguard (AVD) Reports FY 2025 Results, Citing Transformation Success

American Vanguard (NYSE: AVD) reported its full-year 2025 financial results, highlighting a return to growth following a period of strategic restructuring and inventory destocking in the global agricultural sector. The company emphasized the expansion of its 'Green Solutions' biological portfolio and the successful implementation of its business transformation initiative.

3 sources

American Vanguard is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.